InMode Ltd. (NASDAQ:INMD) Shares Bought by Barclays PLC

Barclays PLC increased its holdings in InMode Ltd. (NASDAQ:INMD) by 113.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 169,630 shares of the healthcare company’s stock after buying an additional 90,173 shares during the period. Barclays PLC owned about 0.20% of InMode worth $2,876,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Doma Perpetual Capital Management LLC boosted its stake in InMode by 210.7% in the second quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock valued at $36,685,000 after acquiring an additional 1,363,841 shares during the period. Federated Hermes Inc. increased its position in InMode by 191.9% in the second quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock worth $20,520,000 after buying an additional 739,629 shares during the period. Acadian Asset Management LLC lifted its stake in InMode by 63.6% in the second quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock valued at $20,502,000 after buying an additional 437,122 shares during the last quarter. Lombard Odier Asset Management Europe Ltd acquired a new position in shares of InMode during the second quarter valued at $4,104,000. Finally, Systematic Financial Management LP grew its position in shares of InMode by 34.5% during the second quarter. Systematic Financial Management LP now owns 866,619 shares of the healthcare company’s stock worth $15,807,000 after acquiring an additional 222,532 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on INMD. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Barclays reduced their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Monday, October 14th. Finally, BTIG Research initiated coverage on InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $22.60.

InMode Price Performance

InMode stock opened at $17.06 on Wednesday. InMode Ltd. has a 12-month low of $14.87 and a 12-month high of $26.80. The stock has a market capitalization of $1.43 billion, a PE ratio of 9.22 and a beta of 2.07. The firm has a 50 day simple moving average of $18.28 and a 200-day simple moving average of $17.42.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.